The RNA-binding Protein MEX3B Mediates Resistance to Cancer Immunotherapy by Downregulating HLA-A Expression
Open accessPublished version of a preprint
The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
Purpose: Cancer immunotherapy has shown promising clinical outcomes in many patients. However, some patients still fail to respond, and new strategies are needed to overcome resistance. The purpose of this study was to identify novel genes and understand the mechanisms that confer resistance to cancer immunotherapy. Experimental Design: To identify genes mediating resistance to T-cell killing, we performed an open reading frame (ORF) screen of a kinome library to study whether overexpression of a gene in patient-derived melanoma cells could inhibit their susceptibility to killing by autologous tumor-infiltrating lymphocytes (TIL). Results: The RNA-binding protein MEX3B was identified as a top candidate that decreased the susceptibility of melanoma cells to killing by TILs. Further analyses of anti–PD-1–treated melanoma patient tumor samples suggested that higher MEX3B expression is associated with resistance to PD-1 blockade. In addition, significantly decreased levels of IFNγ were secreted from TILs incubated with MEX3B-overexpressing tumor cells. Interestingly, this phenotype was rescued upon overexpression of exogenous HLA-A2. Consistent with this, we observed decreased HLA-A expression in MEX3B-overexpressing tumor cells. Finally, luciferase reporter assays and RNA-binding protein immunoprecipitation assays suggest that this is due to MEX3B binding to the 3′ untranslated region (UTR) of HLA-A to destabilize the mRNA. Conclusions: MEX3B mediates resistance to cancer immunotherapy by binding to the 3′ UTR of HLA-A to destabilize the HLA-A mRNA and thus downregulate HLA-A expression on the surface of tumor cells, thereby making the tumor cells unable to be recognized and killed by T cells. Clin Cancer Res; 24(14); 3366–76. ©2018 AACR. See related commentary by Kalbasi and Ribas, p. 3239
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For example, MEX3B, a gene responsible for downregulating MHC I expression in tumors, was expressed at higher levels in nonresponders to anti-PD-1 than in responders (96).”
From Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance (2021) · cites this paper as [96]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838 · cited 1×
“However, these durable responses are only achieved in a subset of patients, and currently there is very limited ability to predict whether a patient is likely to respond to immunotherapy (1, 4, 6).”
BackgroundNivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447
Molecular and genetic properties of tumors associated with local immune cytolytic activity
Rooney, M. S., Shukla, S. A., Wu, C. J., Getz, G., & Hacohen, N. (2015) · Cell · doi:10.1016/j.cell.2014.12.033 · Cited by 3,825 · cited 1×
“We first analyzed patient profiles from the TCGA skin cutaneous melanoma database and identified inverse associations between the expression of MEX3B and two indicators of antitumor immune responses, including the RNA-Seq–based immune cytolytic activity score (24) and the IHC-based lymphocyte score, a semiquantitative…”
MethodGenomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
Hugo, W., Zaretsky, J. M., Sun, L., Song, C., Moreno, B. H., Hu-Lieskovan, S., Berent-Maoz, B., Pang, J., Chmielowski, B., Cherry, G., et al. (2016) · Cell · doi:10.1016/j.cell.2016.02.065 · Cited by 3,448 · cited 3×
“The RNA-Seq data from patients with melanoma treated with anti–PD-1 were derived from a published dataset (21).”
BackgroundMethodInfluentialSelf-citationMutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
Zaretsky, J. M., Garcia-Diaz, A., Shin, D. S., Escuin-Ordinas, H., Hugo, W., Hu-Lieskovan, S., Torrejon, D. Y., Abril-Rodriguez, G., Sandoval, S., Barthly, L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1604958 · Cited by 3,237 · cited 1×
“Furthermore, analysis of tumors from patients with melanoma who progressed after initially responding to anti–PD-1 therapy revealed that acquired resistance to anti– PD-1 was associated with mutations in genes involved in interferon receptor signaling and antigen presentation (12).”
BackgroundSelf-citationGenomic classification of cutaneous melanoma
Akbani, R., Akdemir, K. C., Aksoy, B. A., Albert, M., Ally, A., Amin, S. B., Arachchi, H., Arora, A., Auman, J. T., Ayala, B., et al. (2015) · Cell · doi:10.1016/j.cell.2015.05.044 · Cited by 3,151
Self-citationMelanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
Spranger, S., Bao, R., & Gajewski, T. F. (2015) · Nature · doi:10.1038/nature14404 · Cited by 2,830
Research works printed but not linked: 1
- Champion ChiP Transcription Factor Search Portal. 2012–05–12 ed. Valencia (CA): Qiagen; c2000.
Cited by
Bagchi, S., Yuan, R., & Engleman, E. G. (2021) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-042020-042741 · Cited by 2,189
Saxena, M., van der Burg, S. H., Melief, C. J. M., & Bhardwaj, N. (2021) · Nature reviews. Cancer · doi:10.1038/s41568-021-00346-0 · Cited by 1,581
Tumour-intrinsic resistance to immune checkpoint blockade
Kalbasi, A., & Ribas, A. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-019-0218-4 · Cited by 1,486
Melief, C. J. M., van Hall, T., Arens, R., Ossendorp, F., & van der Burg, S. H. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80009 · Cited by 1,164
Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition
Litchfield, K., Reading, J. L., Puttick, C., Thakkar, K., Abbosh, C., Bentham, R., Watkins, T. B. K., Rosenthal, R., Biswas, D., Rowan, A., et al. (2021) · Cell · doi:10.1016/j.cell.2021.01.002 · Cited by 893
Metadata
- Authors
- Huang, L., Malu, S., McKenzie, J. A., Andrews, M. C., Talukder, A. H., Tieu, T., Karpinets, T., Haymaker, C., Forget, M.-A., Williams, L. J., Wang, Z., Mbofung, R. M., Wang, Z.-Q., Davis, R. E., Lo, R. S., Wargo, J. A., Davies, M. A., Bernatchez, C., Heffernan, T., Amaria, R. N., Korkut, A., Peng, W., Roszik, J., Lizée, G., Woodman, S. E., & Hwu, P.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- 5Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas.
- University of California, Los Angeles (US)
- 1Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
- Corresponding author
- Hwu, Patrick
- ORCID
- Huang, Lu
- McKenzie, Jodi A.
- Andrews, Miles C.
- Karpinets, Tatiana
- Haymaker, Cara
- Forget, Marie-Andrée
- Williams, Leila J.
- Wang, Zhe
- Mbofung, Rina M.
- Davis, Richard Eric
- Lo, Roger S.
- Wargo, Jennifer A.
- Davies, Michael A.
- Bernatchez, Chantale
- Heffernan, Timothy
- Amaria, Rodabe N.
- Korkut, Anil
- Peng, Weiyi
- Roszik, Jason
- Woodman, Scott E.
- Hwu, Patrick
- Venue
- Clinical Cancer Research
- Published
- 2018-07-15
- Volume
- 24
- Issue
- 14
- Pages
- 3366-3376
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- PMC
- PMC9872773
- OpenAlex
- W2792458296
- Cited by
- 102
- References
- 30
- Citations by year
- 2026: 5 · 2025: 6 · 2024: 14 · 2023: 15 · 2022: 15 · 2021: 19 · 2020: 15 · 2019: 11 · 2018: 1
- FWCI
- 4.32
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Clinical Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- HHS | National Institutes of Health (NIH) (R01CA184845, R01CA187076, P50CA093459, P30CA016672)
- Dr. Miriam and Sheldon G. Adelson Medical Research Foundation (AMRF)
- Talla Family Revocable Trust
- AIM at Melanoma (AIM at Melanoma Foundation)
- Miriam and Jim Mulva Research Fund
- Jurgen Sager and Transocean Melanoma Research Fund
- El Paso Foundation for Melanoma Research
- Cancer Prevention and Research Institute of Texas (CPRIT) (RP170401, RP140106, RP170067)
- MDACC melanoma moonshots program
- Melanoma Research Alliance (MRA)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- HLA-A, cancer immunotherapy resistance, anti-PD-1 therapy, melanoma, tumor-infiltrating lymphocytes, T cell-mediated killing, interferon-gamma, mRNA destabilization, 3' untranslated region, RNA-binding proteins, HLA downregulation
- MeSH terms
- Antineoplastic Agents, Immunological, Cytotoxicity, Immunologic, Humans, Interferon-gamma, Melanoma, Neoplasms, Protein Binding, Biomarkers, Tumor, HLA-A Antigens, Gene Expression Regulation, Neoplastic, Lymphocytes, Tumor-Infiltrating, RNA-Binding Proteins, Genes, Reporter, Drug Resistance, Neoplasm, 3' Untranslated Regions, Cell Line, Tumor, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The RNA-binding Protein MEX3B Mediates Resistance to Cancer Immunotherapy by Downregulating HLA-A Expression. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-17-2483
- The paper
- Huang, L., Malu, S., McKenzie, J. A., Andrews, M. C., Talukder, A. H., Tieu, T., Karpinets, T., Haymaker, C., Forget, M.-A., Williams, L. J., Wang, Z., Mbofung, R. M., Wang, Z.-Q., Davis, R. E., Lo, R. S., Wargo, J. A., Davies, M. A., Bernatchez, C., Heffernan, T., . . . Hwu, P. (2018). The RNA-binding Protein MEX3B Mediates Resistance to Cancer Immunotherapy by Downregulating HLA-A Expression. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-17-2483
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.